Gait Speed as a Digital Biomarker

Gait speed is the distance a person covers per unit of time while walking, usually reported in metres per second. It is often called the sixth vital sign because it reflects the combined performance of the musculoskeletal, cardiovascular and nervous systems. In a landmark pooled analysis of over 34,000 older adults, faster gait speed predicted longer survival, and a change of about 0.1 m/s is widely treated as clinically meaningful. Traditionally, gait speed was captured only during short supervised walks in clinic. As a digital biomarker, it is measured continuously in daily life with wearable sensors, which reveals real-world walking behaviour rather than a single best effort. That distinction matters: real-world gait speed is typically slower than clinic-measured speed and declines earlier in many conditions, making it a sensitive early signal of functional change.

Wearable devices estimate gait speed from motion data. An accelerometer and gyroscope, worn on the wrist, lower back or thigh, detect walking bouts, individual steps and stride timing. Algorithms then combine cadence and estimated stride length into speed, and GPS can supplement outdoor walks. Research-grade placement on the lower back gives the most accurate stride reconstruction, while wrist-worn consumer devices trade some accuracy for comfort and scale. The Mobilise-D consortium has published a standardised pipeline that estimates real-world walking speed from a single lower-back sensor and has benchmarked its algorithms across chronic conditions. In clinic, instrumented walkways and stopwatch-timed 4-metre walks remain the reference standards against which digital estimates are validated.

Gait speed is used across clinical research as a monitoring and prognostic measure. It supports frailty and falls assessment in older adults, tracks disease progression and treatment response in Parkinson's disease, multiple sclerosis, COPD and heart failure, and measures recovery after stroke or surgery. In rehabilitation studies, continuous gait speed shows whether improvements seen in clinic carry over into daily life. Regulators have accepted gait-derived measures too: stride velocity 95th centile, a related wearable measure of near-maximal walking speed, is qualified by the EMA as a primary endpoint in ambulant Duchenne muscular dystrophy. Trials increasingly pair continuous gait data with patient-reported outcomes to link objective movement with how patients actually feel and function.

Accuracy depends on sensor placement: wrist-worn devices estimate gait speed less precisely than lower-back sensors, especially at the slow speeds common in impaired populations. Algorithms differ between vendors, so values are not directly comparable across devices. Real-world gait speed also varies with environment, footwear and walking purpose, so multi-day averages are needed for stable estimates. Finally, most reference data come from supervised tests, and real-world normative ranges are still being established.

• Studenski S, et al. Gait speed and survival in older adults. JAMA. 2011. pubmed.ncbi.nlm.nih.gov
• Kirk C, et al. Mobilise-D insights to estimate real-world walking speed in multiple conditions with a wearable device. Sci Rep. 2024. pubmed.ncbi.nlm.nih.gov
• European Medicines Agency. Qualification opinion on stride velocity 95th centile as primary endpoint in studies in ambulatory Duchenne muscular dystrophy. 2023. ema.europa.eu
• Middleton A, et al. Walking speed: the functional vital sign. J Aging Phys Act. 2015. pubmed.ncbi.nlm.nih.gov